Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 15/20 | 0.62 |
| ▸ | HTR1D | P28221 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.52 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | TOP2A | P11388 | 1/20 | 0.50 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7011598 | 0.79 | PDCD1LG2 (0.64) | NISCHHTR1DADRA1APDCD1LG2CD274 | |
| SCHEMBL5476725 | 0.78 | NISCH (0.79) | NISCHHTR1DADRA1ALMNARECQL | |
| SCHEMBL1886692 | 0.77 | NISCH (1.00) | NISCHHTR1DADRA1ALMNARECQL | |
| SCHEMBL23073745 | 0.76 | NISCH (0.54) | NISCHHTR1DADRA1APDCD1LG2CD274 | |
| SCHEMBL18704386 | 0.75 | NISCH (0.61) | NISCHHTR1DADRA1APDCD1LG2CD274 | |
| SCHEMBL2427129 | 0.74 | NISCH (1.00) | NISCHLMNARECQL | |
| SCHEMBL8973479 | 0.74 | NISCH (0.61) | NISCHHTR1DADRA1APDCD1LG2CD274 | |
| SCHEMBL2518908 | 0.73 | NISCH (0.66) | NISCHHTR1DADRA1ALMNARECQL | |
| SCHEMBL2361324 | 0.73 | NISCH (0.53) | NISCHHTR1DADRA1APDCD1LG2CD274 | |
| SCHEMBL20355569 | 0.71 | GPR119 (0.48) | NISCHPDCD1LG2CD274LMNARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373948-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Astellas Engineered Small Molecules US, Incorporated | 2023-11-23 | — | — | US | disclosed |
| US-11578052-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | MITOBRIDGE, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20210253549-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2021-08-19 | — | — | US | disclosed |
| US-10399958-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | MITOBRIDGE, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190084958-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE, INC. (US) | 2019-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253549-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARD, PPARA | NISCH 4175/4885HTR1D 1325/4885ADRA1A 77/4885 |
| US-20190084958-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARA, PPARD | NISCH 4330/4885HTR1D 1554/4885ADRA1A 136/4885 |
| US-10399958-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | PPARG, PPARA, PPARD | NISCH 4330/4885HTR1D 1554/4885ADRA1A 136/4885 |
| US-20230373948-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARD, PPARA | NISCH 4175/4885HTR1D 1325/4885ADRA1A 77/4885 |
| US-11578052-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | PPARG, PPARD, PPARA | NISCH 4175/4885HTR1D 1325/4885ADRA1A 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.